[{"data":1,"prerenderedAt":40},["ShallowReactive",2],{"$f-y7eSj73Caurbi1_L33ix6pfx-7ds3L9M05EjN4bf4k":3},{"code":4,"show":5,"msg":6,"data":7,"status":39},1,0,"",{"info":8,"next":20,"prev":25,"others":31},{"cate_name":9,"id":10,"cid":11,"title":12,"desc":13,"title_cn":14,"desc_cn":15,"content_cn":16,"image":17,"content":18,"is_show":4,"home_recommend":4,"publish_at":19},"好物",6,3,"SciBrunch Therapeutics Enters into Exclusive Global License Agreement with MSD for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor","SHANGHAI, China, September 28, 2026 – SciBrunch Therapeutics Co., Ltd. (“SciBrunch”) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that they have entered into an exclusi","思璞锐与默沙东就在研口服KRAS G12D (ON) 抑制剂SPR2015达成全球独家授权协议","中国上海，2026年9月28日——上海思璞锐医药科技有限公司（SciBrunch Therapeutics Co., Ltd.，以下简称“思璞锐”），与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）今日共同宣布，双方已就在研临床前口服KRAS G12D (ON) 抑制剂SPR2015达成全球独家授权协议。","\u003Cp>中国上海，2026年9月28日——上海思璞锐医药科技有限公司（SciBrunch Therapeutics Co., Ltd.，以下简称“思璞锐”），与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）今日共同宣布，双方已就在研临床前口服KRAS G12D（ON）抑制剂SPR2015达成全球独家授权协议。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>思璞锐创始人、董事长兼首席执行官胡滔博士表示:“自创立伊始，思璞锐始终专注于推进靶向RAS通路创新疗法的开发，致力于为胰腺癌、结直肠癌、肺癌及其他重大恶性肿瘤患者提供突破性治疗方案。此次与默沙东达成合作不仅体现了思璞锐平台的研发实力，也进一步彰显了SPR2015在解决肿瘤领域长期未满足的医疗需求方面的潜力。我们非常期待由全球肿瘤领域领导者默沙东继续推进SPR2015的开发。”\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>根据协议条款，思璞锐已授予默沙东SPR2015在全球范围内开发、生产及商业化的独家权利。思璞锐将获得4亿美元首付款，并有资格获得与多个适应症相关的开发、商业化及其他活动有关的特定里程碑付款。包括首付款在内，本次交易的潜在总价值最高可达21.3亿美元。该交易已完成交割。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>默沙东研究实验室药物发现、临床前开发及转化医学高级副总裁George Addona表示：“越来越多的证据显示，靶向KRAS通路具有重要的治疗潜力，该通路在肿瘤细胞生长中的作用已得到广泛研究。此次合作将SPR2015这一针对人类癌症中最常见KRAS突变类型之一的强效工程化抑制剂纳入我们的研发管线，进一步丰富和拓展了默沙东持续布局的精准靶向候选药物组合。”\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>\u003Cstrong>关于SPR2015\u003C/strong>\u003C/h3>\u003Cp>SPR2015是一款高效、高选择性的新型在研临床前分子胶型KRAS G12D（ON）抑制剂，在多种KRAS G12D突变肿瘤细胞系中展现出纳摩尔级增殖抑制活性，并保持对KRAS野生型的良好选择性。KRAS G12D是人类肿瘤中最常见的致癌性RAS突变，由第12位甘氨酸（G）突变为天冬氨酸（D）所致。该突变使KRAS持续处于活化状态，并持续传递促进细胞增殖和存活的信号。在2026年美国癌症研究协会（AACR）年会上，思璞锐公布的临床前研究结果显示，SPR2015已在多种体内细胞源性及患者源性异种移植（CDX/PDX）模型中作为单药展现出显著的抗肿瘤活性。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>\u003Cstrong>关于思璞锐\u003C/strong>\u003C/h3>\u003Cp>上海思璞锐医药科技有限公司（SciBrunch Therapeutics Co., Ltd.）创立于2024年底，总部位于上海，是一家处于临床阶段的研发型生物技术公司，专注小分子抗肿瘤药物迭代创新。公司由资深连续创业者胡滔博士携手药物化学专家张杨博士共同创立，以新视角挖掘临床验证靶点的开发潜力，前瞻性地进行差异化的产品性能设计，秉承“做对、做深、做极致”的药物研发理念，打造具有全球竞争力的产品。欲了解更多信息，请访问 \u003Ca href=\"https://www.scibrunch.com\" target=\"_blank\">https://www.scibrunch.com\u003C/a>。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>\u003Cstrong>关于默沙东\u003C/strong>\u003C/h3>\u003Cp>在默沙东（在美国和加拿大称为美国新泽西州罗威市默克公司），我们齐心协力追求共同的目标：我们发挥前沿科学的力量，在全球范围内拯救生命、改善生活。130多年来，我们通过研发重要药物和疫苗，为全人类带来希望。我们致力成为顶尖的研究密集型生物制药公司——当下，我们正处于研发前线，推出创新解决方案，以推进人类和动物疾病的预防和治疗。我们建立了一个多元、包容的全球员工体系，以负责的态度经营每一天，确保所有人、所有社区都能有一个安全、可持续和健康的未来。更多信息，请访问\u003Ca href=\"https://www.msd.com\" target=\"_blank\">https://www.msd.com\u003C/a>，并在\u003Ca href=\"https://x.com/MSDInvents\" target=\"_blank\">X（前身为Twitter）\u003C/a>、\u003Ca href=\"https://www.linkedin.com/company/msd-global/posts/?feedView=all\" target=\"_blank\">LinkedIn\u003C/a>和\u003Ca href=\"https://www.youtube.com/channel/UChHvXY_b3cgM_Bvb2J-B5-Q\" target=\"_blank\">YouTube\u003C/a>平台关注我们。\u003C/p>","https://api-scibrunch.hellokoma.com/uploads/images/20260928/2026092814375599fd00500.jpg","\u003Cp>SHANGHAI, China, September 28, 2026 – SciBrunch Therapeutics Co., Ltd. (“SciBrunch”) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>“Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors,” said Tao Hu, founder, chairman and chief executive officer of SciBrunch. “This agreement with MSD not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology. We are excited that MSD, a global leader in oncology, will take SPR2015 forward.”\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of $400 million and is eligible to receive payments associated with the achievement of certain milestones related to development, commercialization and other activities across multiple indications. The total potential aggregate value of the transaction, including the upfront payment, is $2.13 billion. The transaction has closed.\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,\" said George Addona, senior vice president, discovery, preclinical development and translational medicine, MSD Research Laboratories. “This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers.”\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>About SPR2015\u003C/h3>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>SPR2015 is a potent and selective novel investigational preclinical molecular glue KRAS G12D (ON) inhibitor that has demonstrated nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells. KRAS G12D is the most common oncogenic RAS mutation in human tumors which results from a substitution of glycine with aspartate at position 12. This change leaves KRAS active and continuously signaling for cell proliferation and survival. In addition, SPR2015 has demonstrated compelling antitumor efficacy as a monotherapy across multiple in vivo cell-derived and patient-derived xenograft (CDX/PDX) models, as reported in preclinical data presented at the 2026 AACR Annual Meeting.\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>About SciBrunch\u003C/h3>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>SciBrunch Therapeutics Co., Ltd., founded in late 2024, is a clinical-stage biotech driven by iterative innovation in small molecule oncology therapeutics, headquartered in Shanghai. Founded by serial entrepreneur Dr. Tao Hu together with seasoned medicinal chemist Dr. Yang Zhang, the company leverages novel scientific insights to unlock the potential of clinically validated targets and applies forward-looking, differentiated product design strategies. Guided by its philosophy of “doing the right thing, going deep, and pursuing excellence,” SciBrunch aims to build globally competitive products. For more information, visit \u003Ca href=\"https://www.scibrunch.com\" target=\"_blank\">https://www.scibrunch.com\u003C/a>.\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>About MSD\u003C/h3>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit \u003Ca href=\"https://www.msd.com\" target=\"_blank\">https://www.msd.com\u003C/a> and connect with us on \u003Ca href=\"https://x.com/MSDInvents\" target=\"_blank\">X (formerly Twitter)\u003C/a> \u003Ca href=\"https://www.linkedin.com/company/msd-global/posts/?feedView=all\" target=\"_blank\">LinkedIn\u003C/a> and \u003Ca href=\"https://www.youtube.com/channel/UChHvXY_b3cgM_Bvb2J-B5-Q\" target=\"_blank\">YouTube\u003C/a>.\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3>Advisors\u003C/h3>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>BofA Securities acted as exclusive financial advisor to SciBrunch in connection with the transaction.\u003C/p>",1790561873,{"publish_time":21,"id":4,"title":22,"title_cn":23,"publish_at":24},"2025-06-05","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","思璞锐完成超2亿元天使轮融资，专注小分子抗肿瘤创新药开发",1749101112,{"publish_time":26,"id":27,"title":28,"title_cn":29,"publish_at":30},"2026-01-30",4,"SciBrunch Therapeutics Completes Over $35 Million Pre-A Round Financing, Totaling $65 Million in Two Recent Rounds","思璞锐SciBrunch完成超3500万美元Pre-A轮融资，近期两轮融资合计6500万美元",1769702400,[32,33,38],{"publish_time":26,"id":27,"title":28,"title_cn":29,"publish_at":30},{"publish_time":34,"id":11,"title":35,"title_cn":36,"publish_at":37},"2026-01-09","First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","首例患者入组！思璞锐启动高选择性PARP1抑制剂SPR1020临床I期试验",1767936313,{"publish_time":21,"id":4,"title":22,"title_cn":23,"publish_at":24},200,1790595659971]